Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea
· Delayed Price · Currency is KRW 481,500
-34,500 (-6.69%)
At close: Mar 9, 2026
Hanmi Pharm. Revenue
Hanmi Pharm. had revenue of 362.35B KRW in the quarter ending September 30, 2025, with 0.07% growth. This brings the company's revenue in the last twelve months to 1.47T, down -6.39% year-over-year. In the year 2024, Hanmi Pharm. had annual revenue of 1.50T with 0.31% growth.
Revenue (ttm)
1,466.18B
Revenue Growth
-6.39%
P/S Ratio
4.16
Revenue / Employee
610.91M
Employees
2,400
Market Cap
6,105.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,495.50B | 4.61B | 0.31% |
| Dec 31, 2023 | 1,490.89B | 159.34B | 11.97% |
| Dec 31, 2022 | 1,331.55B | 128.36B | 10.67% |
| Dec 31, 2021 | 1,203.19B | 127.33B | 11.84% |
| Dec 31, 2020 | 1,075.85B | -37.80B | -3.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Yuhan | 2,136.67B |
| Hanall Biopharma | 154.05B |
| Celltrion Pharm | 274.73B |
| Daewoong Pharmaceutical | 1,541.65B |
| GC Biopharma | 1,934.38B |
| Chong Kun Dang Pharmaceutical | 1,680.99B |
| Ildong Pharmaceutical | 575.66B |
| Daewoong | 2,055.93B |